Xenon Pharmaceuticals (XENE) reported a Q1 net loss late Monday of $0.83 per diluted share, widening from a loss of $0.62 a year earlier.
Analysts polled by FactSet expected a loss of $0.91.
Revenue for the three months ended March 31 was $7.5 million, compared with nil a year earlier. Analysts expected $2.2 million.
Based on current operating plans, Xenon said it anticipates having sufficient cash to fund operations into 2027.
Shares of the company were down more than 13% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.